BIOAGE Labs Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, everyone. Thank you for joining us. Really pleased to have with us the BIOAGE team. We have BJ Sullivan, Chief Strategy Officer and Dove Goldstein, CFO.
Questions & Answers
To start here, the company's developing its NLRP3 inhibitor BGE-102 in cardiovascular risk and ophthalmology, and also advancing a pipeline of APJ agonists. Can you walk us through the portfolio strategy where the assets stand today and the data expected over the next 12 months?
Yeah, one, thank you for having us. Great to be here. So we are a clinical stage biotech company and we are applying human aging biology as a lens for target discovery and development of therapies for cardiometabolic disease.
As you mentioned, our lead program is BG-102. It's a potential best in class NLRP3 inhibitor. So we recently released our full Phase 1 data, which included two cohorts of obese subjects with elevated inflammation at baseline. And
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
